These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24348057)

  • 1. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():611-21. PubMed ID: 24348057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy.
    Mencacci C; Di Sciascio G; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():87-99. PubMed ID: 23413176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
    Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
    De Salas-Cansado M; Olivares JM; Alvarez E; Carrasco JL; Barrueta A; Rejas J
    Clinicoecon Outcomes Res; 2012; 4():157-68. PubMed ID: 22745564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
    Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
    Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
    Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
    Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
    Freeman H; Arikian S; Lenox-Smith A
    Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH; Gordon LG
    Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder.
    Liu X; Chen Y; Faries DE
    Clinicoecon Outcomes Res; 2011; 3():63-72. PubMed ID: 21935334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of antidepressants in depression: A systematic review and meta-analysis.
    Yuan Z; Chen Z; Xue M; Zhang J; Leng L
    J Clin Neurosci; 2020 Oct; 80():169-181. PubMed ID: 33099342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.
    Einarson TR; Arikian S; Sweeney S; Doyle J
    Clin Ther; 1995; 17(1):136-53. PubMed ID: 7758056
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.